TxCell Lands $16M to Advance Immunotherapy for Crohn's
Continuing Europe's recent push in cell therapy development, TxCell SA raised €12.4 million (US$16.1 million) in a Series C round to fund a Phase IIb study of its OvaSave autologous cell therapy in patients with refractory Crohn's disease.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST